{"url_path":"/sec/rani/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001193125-26-226703-index.html","accession_number":"0001193125-26-226703","cik":"0001856725","ticker":"RANI","issuer_name":"Rani Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001193125-26-226703-index.html","primary_entity_key":"0001856725","primary_entity_name":"Rani Therapeutics Holdings, Inc."},"word_count":412,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nThe following is a list of all exhibits filed or furnished as part of this report:\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated December 31, 2025, filed with the SEC on January 2, 2026).](https://www.sec.gov/Archives/edgar/data/1856725/000119312521223596/d151628dex31.htm)\n\n3.2\n\n \n\n[Amended and Restated Bylaws of the Registrant as currently in effect (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K dated December 31, 2025, filed with the SEC on January 2, 2026).](https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/d848686dex32.htm)\n\n10.1*\n\n \n\n[Rani Therapeutics Holdings, Inc. Non-Employee Director Compensation Policy.](rani-ex10_1.htm)\n\n10.2*\n\n \n\n[First Amendment to ProGen Collaboration Agreement dated January 13, 2026.](rani-ex10_2.htm)\n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](rani-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](rani-ex31_2.htm)\n\n32.1*†\n\n \n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](rani-ex32_1.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\n\nFiled herewith.\n\n†\n\nThe certifications attached as Exhibit 32.1 which accompanies this Quarterly Report on Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.\n\n \n\n36\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nRani Therapeutics Holdings, Inc.\n\nDate: May 15, 2026\n\nBy:\n\n/s/ Talat Imran\n\nTalat Imran\n\nChief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\nDate: May 15, 2026\n\nBy:\n\n/s/ Svai Sanford\n\n \n\n \n\n \n\nSvai Sanford\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n37"}